Insider Trading February 13, 2026

P&G CHRO Completes $2.06M Stock Sale, Exercises Options in Parallel

Transaction details: 12,827 shares sold at about $160.31 and the same number acquired via option exercise at $91.07; company posts mixed fiscal Q2 2026 results

By Sofia Navarro PG
P&G CHRO Completes $2.06M Stock Sale, Exercises Options in Parallel
PG

Balaji Purushothaman, Procter & Gamble’s Chief Human Resources Officer, sold 12,827 shares of common stock on February 11, 2026, for a weighted average price of $160.3093, raising $2,056,287. On the same day he exercised options to acquire 12,827 shares at $91.07, a transaction valued at $1,168,154. Following these moves he directly holds 12,638.8004 shares and indirectly holds 5,223.363 shares through a retirement plan trustee. Separately, Procter & Gamble reported fiscal second-quarter 2026 earnings with EPS of $1.88, slightly above the $1.86 consensus, while revenue of $22.2 billion missed the $22.34 billion consensus. Several analysts adjusted their targets and ratings following the quarter.

Key Points

  • Balaji Purushothaman sold 12,827 P&G shares on February 11, 2026 at a weighted average price of $160.3093, netting $2,056,287.
  • On the same day he exercised options for 12,827 shares at $91.07, at an aggregate cost of $1,168,154; post-transactions he directly owns 12,638.8004 shares and indirectly holds 5,223.363 shares through a retirement plan trustee.
  • Procter & Gamble’s fiscal Q2 2026 showed EPS of $1.88 (consensus $1.86) and revenue of $22.2 billion (consensus $22.34 billion); several analysts raised price targets and adjusted ratings.

Summary of insider activity

Procter & Gamble’s Chief Human Resources Officer, Balaji Purushothaman, executed a sale of 12,827 shares of the company’s common stock on February 11, 2026. The shares were disposed of at a weighted average price of $160.3093, with execution prices spanning from $160.30 to $160.36, producing proceeds of $2,056,287.

Concurrent option exercise

On the same date, Purushothaman exercised stock options to obtain 12,827 shares of Procter & Gamble common stock at an exercise price of $91.07 per share, for an aggregate option exercise value of $1,168,154.

Post-transaction holdings

After accounting for both the sale and the option exercise, Purushothaman’s reported holdings include a direct ownership stake of 12,638.8004 shares and an indirect holding of 5,223.363 shares held through a retirement plan trustee.


Company results reported alongside the filings

Separately from the insider filings, Procter & Gamble disclosed its fiscal second-quarter 2026 results. The company reported earnings per share of $1.88, which modestly exceeded the consensus estimate of $1.86. However, revenue for the quarter was reported at $22.2 billion, falling short of the expected $22.34 billion.

Analyst reactions noted in filings

Following the quarter, several Wall Street firms adjusted their assessments of Procter & Gamble. UBS raised its price target to $170 while maintaining a Buy rating. Wells Fargo increased its target to $165 with an Overweight rating. BofA Securities nudged its target up to $171 and kept a Buy rating. JPMorgan upgraded the stock to Overweight, citing the potential for improved organic sales growth and better margins in the medium term.


What the public record shows and what it does not

The regulatory filings provide transaction-level detail on the sale and option exercise and disclose updated ownership amounts. They do not include explanatory commentary from the officer on motivations for the sale or the option exercise. Likewise, the filings and the company’s reported quarter present financial metrics and analysts’ revised views, but do not connect the insider activity to the company’s quarterly performance.

Contextual note

The available documentation is limited to the figures and statements recorded: specific share counts and prices for the transactions on February 11, 2026; the officer’s resulting direct and indirect holdings; the company’s fiscal second-quarter 2026 EPS and revenue versus consensus figures; and the analysts’ updated price targets and ratings as reported.

Risks

  • Quarterly revenue missed consensus ($22.2 billion versus $22.34 billion), creating uncertainty about near-term top-line momentum - this affects consumer staples and equity market sentiment.
  • The public filings disclose transaction amounts and holdings but do not provide the officer’s rationale for the sale or exercise, leaving motivations and timing unexplained - this is a disclosure limitation for investors evaluating insider activity.
  • Analyst upgrades and higher price targets reflect optimism, but the revenue shortfall introduces a risk that the company may need to demonstrate sustained organic sales growth and margin improvement to meet those expectations - relevant to equity analysts and fixed-income investors assessing corporate fundamentals.

More from Insider Trading

Clean Harbors Director Executes $204,802 Sale as Company Reports Strong Q4 and Pushes M&A Agenda Feb 21, 2026 Clean Harbors Executive Disposes Nearly $1.0M in Stock as Company Posts Strong Q4 Feb 21, 2026 Clean Harbors CFO Disposes $784K in Shares as Company Reports Strong Quarter and Pursues Acquisition Feb 21, 2026 Travelers Executive Vice President Records $1.74 Million Share Sale as Company Posts Strong Quarter Feb 21, 2026 Genasys Director Buys $50,404 of Stock; Company Reports Mixed Q1 Results Feb 21, 2026